Home/Oragenics/Janet Huffman
JH

Janet Huffman

Investor Relations Contact

Oragenics

Oragenics Pipeline

DrugIndicationPhase
ONP-002Concussion / mild Traumatic Brain Injury (mTBI)Phase 2
ONP-001Rare Leukodystrophies (e.g., Niemann-Pick Disease Type C)Preclinical
NT-CoV-2 (Terra CoV-2)Prevention of COVID-19 and SARS-CoV-2 variantsPreclinical
Lantibiotics ProgramInfections from multidrug-resistant bacteriaNot Disclosed